ARTICLE | Financial News
Alexion reports on Strensiq, Kanuma launches
February 4, 2016 2:05 AM UTC
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) gained $8.61 to $145.97 Wednesday after reporting 4Q15 and full-year earnings, including early sales of Strensiq asfotase alfa and Kanuma sebelipase alfa.
The company reported $11.6 million in Strensiq sales, beating a consensus estimate of $4.6 million. FDA approved the hypophosphatasia treatment in October (see BioCentury Extra, Oct. 26, 2015). ...